医学
梅尔法兰
硼替佐米
依托泊苷
卡莫司汀
内科学
肿瘤科
多发性骨髓瘤
自体干细胞移植
阿糖胞苷
挽救疗法
移植
外科
伏立诺他
联合疗法
化疗
组蛋白脱乙酰基酶
生物化学
化学
基因
组蛋白
作者
Leona Holmberg,David G. Maloney,Laura Connelly‐Smith
出处
期刊:PubMed
日期:2023-09-14
摘要
The success of autologous stem cell transplantation (ASCT) for treating non-Hodgkin's lymphoma (NHL) is limited by its high relapse rates. To reduce the risk of relapse, additional maintenance therapy can be added post-transplant. In a non-transplant setting at the time of initiation of this study, both bortezomib and vorinostat had been studied alone or in combination for some NHL histology and showed some clinical activity. At our center, this combination therapy post-transplant for Multiple Myeloma (MM) showed acceptable toxicity. Therefore, it seemed reasonable to study this combination therapy post-ASCT for NHL.NHL patients underwent conditioning for ASCT with rituximab, carmustine, etoposide, cytarabine, melphalan (R-BEAM)/carmustine, etoposide, cytarabine, melphalan (BEAM). After recovery from the acute transplant-related toxicity, combination therapy with IV bortezomib and oral vorinostat (BV) was started and was given for a total of 12 (28-day) cycles.Nineteen patients received BV post ASCT. The most common toxicities were hematologic, gastrointestinal, metabolic, fatigue and peripheral neuropathy. With a median follow-up of 10.3 years, 11 patients (58%) are alive without disease progression and 12 patients (63%) are alive.BV can be given post-ASCT for NHL and produces excellent disease-free and overall survival rates.
科研通智能强力驱动
Strongly Powered by AbleSci AI